The clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological evaluation.
The platform can help to combine domestic and foreign experts and teams to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner depending on the changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the origins of anti-lipopathic syndrome. The platform serves China International Medical Service System, a team of nationally and internationally authoritative experts in the field of blood tumours, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.